세계의 신생항원 표적 치료제 시장 - 산업 규모, 점유율, 동향, 기회, 예측, 대상 질환별, 네오 안티겐 유형별, 면역 요법 유형별, 투여 경로별, 지역별 부문, 경쟁(2020-2030년)
Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Target Disease Indication, By Neoantigens Type, By Immunotherapy Type, By Route of Administration, By Region & Competition, 2020-2030F
신생항원 표적 치료제 세계 시장 규모는 2024년에 18억 8,000만 달러로 평가되었으며, 2030년까지의 CAGR은 8.34%를 나타낼 전망입니다.
신생항원 표적 치료제는 암세포를 특이적으로 인식하고 공격하는 면역계의 힘을 이용하는 암 치료에 있어서의 최첨단의 접근입니다. 이러한 치료법은 종양의 DNA에 돌연변이가 있기 때문에 암세포의 표면에서 발견되는 독특한 단백질 단편인 네오 안티겐을 표적으로 하도록 설계되었습니다. 예를 들어 2022년 12월에 Indian Journal of Medical Research가 발표한 조사에 따르면 2022년 인도의 신규암 환자수는 1,461,427명으로 추정되었습니다. 이 보고서는 이 나라에서 암 이환 증가를 강조하고 이환율의 상승에 대처하기 위한 의식 향상, 조기 발견, 치료 전략 개선의 필요성을 강조하고 있습니다. 네오 안티겐은 정상적이고 건강한 세포 단백질과 다르므로 면역 인식과 공격의 이상적인 표적이 됩니다. 네오 안티겐 치료는 고도로 개별화되었습니다. 네오 안티겐이 확인되면 환자의 면역계는 이러한 특정 네오 안티겐을 외적으로 인식하도록 훈련됩니다. 이를 위해서는 종종 환자 고유의 네오 안티겐 프로파일에 맞게 맞춤화된 백신과 입양 요법이 필요합니다. 네오 안티겐 요법은 또 다른 면역 요법인 체크 포인트 억제제와 함께 사용할 수 있습니다. 체크포인트 억제제는 면역계의 브레이크를 해제하고 네오 안티겐이 표적으로 하는 암세포를 포함하는 암세포에 대해 보다 강력한 반응을 일으킬 수 있게 합니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
18억 8,000만 달러 |
| 시장 규모 : 2030년 |
30억 2,000만 달러 |
| CAGR : 2025-2030년 |
8.34% |
| 급성장 부문 |
기성품 네오 안티겐 |
| 최대 시장 |
북미 |
유전체 시퀀싱 기술을 이용할 수 있어 가격도 저렴해짐에 따라, 네오 안티겐을 보다 정확하고 신속하게 동정할 수 있게 되어, 맞춤형 치료의 개발이 용이하게 되었습니다. FDA와 EMA와 같은 규제 기관은 네오 안티겐 치료의 개발과 승인에 적극적이며 이러한 치료법 시장 개척을 간소화하고 있습니다. 환자와 의료 제공자는 암세포를 특이적으로 표적으로 하는 정밀 치료를 점점 요구하게 되고 있습니다. 네오 안티겐 치료는 더 효과적이고 독성이 낮은 치료 가능성을 제공합니다. 연구자들은 네오 안티겐 요법을 화학 요법 및 방사선 요법과 같은 다른 치료법과 결합하여 치료 효과를 높이는 시너지 효과를 찾고 있습니다. 고령화 사회는 암 발병 위험이 높습니다. 세계 인구의 고령화에 따라 네오 안티겐 요법을 포함한 혁신적인 암 치료에 대한 수요가 높아질 것으로 예상됩니다.
주요 시장 성장 촉진요인
유전체 검사의 진보
주요 시장 과제
관련 네오 안티겐의 동정
주요 시장 동향
면역 요법의 이점
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 COVID-19가 세계의 신생항원 표적 치료제 시장에 미치는 영향
제5장 고객의 목소리
제6장 세계의 신생항원 표적 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 대상 질환별(골암, 대장암, 부인과암, 비소세포폐암, 신세포암)
- 네오 안티겐 유형별(기성 네오 안티겐, 개별화 네오 안티겐)
- 투여 경로별(피내, 정맥내, 피하)
- 면역요법 유형별(수상세포 백신, DNA/RNA 기반의 백신, 단백질/펩티드 기반의 백신, TIL 기반의 치료법)
- 지역별
- 기업별(2024)
- 시장 맵
제7장 아시아태평양의 신생항원 표적 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제8장 유럽의 신생항원 표적 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제9장 북미의 신생항원 표적 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제10장 남미의 신생항원 표적 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제11장 중동 및 아프리카의 신생항원 표적 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
제12장 시장 역학
제13장 시장 동향과 발전
제14장 세계의 신생항원 표적 치료제 시장 : SWOT 분석
제15장 Porter's Five Forces 분석
- 업계 내 경쟁
- 신규 진입의 가능성
- 공급자의 힘
- 고객의 힘
- 대체품의 위협
제16장 PESTEL 분석
제17장 경쟁 구도
- BioNtech SE
- Gritstone Bio, Inc.
- Genocea Biosciences Inc
- Moderna Inc.
- Agenus Inc.
- Immatics NV
- Advaxis Inc.
- Precision Biologics
- Gilead Sciences, Inc.
- Cellular Biomedicine Group, Inc.
- Achillies Therapeutics Plc.
- Merck & Co, Inc.
제18장 전략적 제안
제19장 기업 소개와 면책사항
SHW
Global Neoantigen Targeted Therapies Market was valued at USD 1.88 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.34% through 2030. Neoantigen Targeted Therapies are a cutting-edge approach in cancer treatment that harnesses the power of the immune system to specifically recognize and attack cancer cells. These therapies are designed to target neoantigens, which are unique protein fragments found on the surface of cancer cells because of mutations in the tumor's DNA. For instance, according to a study published by the Indian Journal of Medical Research in December 2022, the estimated number of new cancer cases in India for 2022 was 14,61,427. The report highlights the growing cancer burden in the country, emphasizing the need for enhanced awareness, early detection, and improved treatment strategies to address the rising incidence. Neoantigens are distinct from normal, healthy cell proteins, making them ideal targets for immune recognition and attack. Neoantigen therapies are highly personalized. Once neoantigens are identified, the patient's immune system is trained to recognize these specific neoantigens as foreign invaders. This often involves creating a customized vaccine or adoptive cell therapy tailored to the patient's unique neoantigen profile. Neoantigen therapies can be used in combination with checkpoint inhibitors, another type of immunotherapy. Checkpoint inhibitors release the brakes on the immune system, allowing it to mount a stronger response against cancer cells, including those targeted by neoantigens.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 1.88 Billion |
| Market Size 2030 | USD 3.02 Billion |
| CAGR 2025-2030 | 8.34% |
| Fastest Growing Segment | Off-the-Shelf Neoantigens |
| Largest Market | North America |
The growing availability and affordability of genomic sequencing technologies have enabled the identification of neoantigens more accurately and quickly, facilitating the development of personalized therapies. Regulatory agencies like the FDA and EMA have shown willingness to support the development and approval of neoantigen therapies, streamlining the path to market for these treatments. Patients and healthcare providers are increasingly seeking precision therapies that specifically target cancer cells. Neoantigen therapies offer the potential for more effective and less toxic treatments. Researchers are exploring the synergistic effects of combining neoantigen therapies with other treatment modalities, such as chemotherapy and radiation therapy, to enhance treatment outcomes. The aging population is at higher risk of developing cancer. As the global population ages, the demand for innovative cancer treatments, including neoantigen therapies, is expected to rise.
Key Market Drivers
Advancements in Genomic Testing
Next-generation sequencing technologies have revolutionized the field of genomics. NGS allows for the rapid and cost-effective sequencing of large stretches of DNA. It has enabled the sequencing of entire genomes, transcriptomes, and epigenomes with unprecedented speed and affordability. For instance, a study published in PNAS in September 2022 reported that researchers developed an antibody-based therapy that successfully eliminated circulating tumor cells (CTCs) in breast cancer mouse models. This breakthrough highlights the potential of targeted immunotherapy in preventing cancer metastasis, offering hope for improved treatment strategies and better outcomes for breast cancer patients in the future. High-throughput sequencing platforms can simultaneously process numerous DNA or RNA samples, allowing for large-scale studies and population-scale genomic research. This capability has accelerated the discovery of genetic variants associated with diseases and traits. Traditional short-read sequencing methods have limitations in resolving complex genomic regions. Long-read sequencing technologies, like Pacific Biosciences (PacBio) and Oxford Nanopore, can generate much longer sequencing reads, aiding in the assembly of complete genomes and the identification of structural variations. Single-cell sequencing technologies enable the analysis of individual cells within a tissue or organism. This approach provides insights into cellular heterogeneity, cell types, and gene expression at a single-cell resolution, advancing our understanding of complex biological systems. Genomic sequencing has been instrumental in cancer research and precision oncology. It allows for the identification of driver mutations, assessment of tumor heterogeneity, and the development of targeted therapies tailored to a patient's genetic profile.
Key Market Challenges
Identification of Relevant Neoantigens
Tumors are often genetically heterogeneous, meaning they contain a mix of different cell types with various mutations. Identifying the specific neoantigens that are present across all tumor cells can be challenging. Neoantigen prediction relies on computational algorithms to predict potential neoantigens based on DNA sequencing data. These algorithms are continually improving, but false positives and false negatives are still common, leading to uncertainty in selecting the most relevant neoantigens. Predicted neoantigens must be experimentally validated to confirm their presentation on cancer cells and their immunogenicity. This validation process can be time-consuming and resource intensive. Each patient's tumor has a unique set of neoantigens, and these can vary greatly from one patient to another. Identifying relevant neoantigens requires a personalized approach for each patient, which can be logistically challenging. Some neoantigens may be present at very low frequencies within a tumor, making them difficult to detect and target effectively. Tumors can evolve over time, leading to changes in their neoantigen landscape. This requires ongoing monitoring and adaptation of neoantigen-targeted therapies. Cancer cells may develop mechanisms to evade the immune system, including downregulating the presentation of neoantigens. This immune evasion can hinder the effectiveness of neoantigen-targeted therapies.
Key Market Trends
Immunotherapy Dominance
Immunotherapy has gained prominence as a leading approach in cancer treatment. It harnesses the body's immune system to target and destroy cancer cells. Neoantigen-targeted therapies are a subset of immunotherapy that focuses on training the immune system to recognize and attack cancer-specific neoantigens. Immunotherapy, including neoantigen-targeted therapies, aligns with the principles of precision medicine. These therapies are tailored to the individual genetic and immunological profiles of each patient, aiming to maximize treatment efficacy while minimizing side effects. Neoantigen-targeted therapies often complement the use of checkpoint inhibitors, another class of immunotherapies. Checkpoint inhibitors release the brakes on the immune system, allowing it to attack cancer cells more effectively. Neoantigens can serve as specific targets for the immune system to recognize in combination with checkpoint inhibitors. Neoantigen-targeted therapies aim to enhance the immune system's response against cancer cells by targeting neoantigens, which are unique to the tumor. This can lead to a more focused and potent immune response compared to traditional treatments. Positive outcomes and clinical successes in immunotherapy trials, including neoantigen therapies, have fueled interest and investment in this field. Patients who have experienced durable responses are advocating for and raising awareness of these treatments. The pharmaceutical and biotechnology industries have invested heavily in the research and development of immunotherapies, including neoantigen-based approaches. This investment has led to a growing pipeline of potential therapies.
Key Market Players
- BioNtech SE
- Gritstone Bio, Inc.
- Genocea Biosciences Inc.
- Moderna Inc
- Agenus Inc.
- Immatics NV
- Advaxis Inc
- Precision Biologics
- Gilead Sciences, Inc.
- Cellular Biomedicine Group Inc.
- Achillies Therapeutics Plc.
- Merck & Co Inc
Report Scope:
In this report, the Global Neoantigen Targeted Therapies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Neoantigen Targeted Therapies Market, By Target Disease Indication:
- Bone Cancer
- Colorectal Cancer
- Gynecological Cancer
- Non-Small Cell Lung Cancer
- Renal Cell Carcinoma
Neoantigen Targeted Therapies Market, By Neoantigens Type:
- Off-the-Shelf Neoantigens
- Personalized Neoantigens
Neoantigen Targeted Therapies Market, By Immunotherapy Type:
- Dendritic Cell Vaccines
- DNA / RNA-Based Vaccines
- Protein / Peptide-based Vaccines
- TIL-Based Therapies
Neoantigen Targeted Therapies Market, By Route of Administration:
- Intradermal
- Intravenous
- Subcutaneous
Neoantigen Targeted Therapies Market, By region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Neoantigen Targeted Therapies Market.
Available Customizations:
Global Neoantigen Targeted Therapies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Applications
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Impact of COVID-19 on Global Neoantigen Targeted Therapies Market
5. Voice of Customer
6. Global Neoantigen Targeted Therapies Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma)
- 6.2.2. By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens)
- 6.2.3. By Route of Administration (Intradermal, Intravenous, Subcutaneous)
- 6.2.4. By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies)
- 6.2.5. By Region
- 6.2.6. By Company (2024)
- 6.3. Market Map
7. Asia Pacific Neoantigen Targeted Therapies Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Target Disease Indication
- 7.2.2. By Neoantigens Type
- 7.2.3. By Route of Administration
- 7.2.4. By Immunotherapy Type
- 7.2.5. By Country
- 7.3. Asia Pacific: Country Analysis
- 7.3.1. China Neoantigen Targeted Therapies Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Target Disease Indication
- 7.3.1.2.2. By Neoantigens Type
- 7.3.1.2.3. By Route of Administration
- 7.3.1.2.4. By Immunotherapy Type
- 7.3.2. India Neoantigen Targeted Therapies Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Target Disease Indication
- 7.3.2.2.2. By Neoantigens Type
- 7.3.2.2.3. By Route of Administration
- 7.3.2.2.4. By Immunotherapy Type
- 7.3.3. Australia Neoantigen Targeted Therapies Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Target Disease Indication
- 7.3.3.2.2. By Neoantigens Type
- 7.3.3.2.3. By Route of Administration
- 7.3.3.2.4. By Immunotherapy Type
- 7.3.4. Japan Neoantigen Targeted Therapies Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Target Disease Indication
- 7.3.4.2.2. By Neoantigens Type
- 7.3.4.2.3. By Route of Administration
- 7.3.4.2.4. By Immunotherapy Type
- 7.3.5. South Korea Neoantigen Targeted Therapies Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Target Disease Indication
- 7.3.5.2.2. By Neoantigens Type
- 7.3.5.2.3. By Route of Administration
- 7.3.5.2.4. By Immunotherapy Type
8. Europe Neoantigen Targeted Therapies Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Target Disease Indication
- 8.2.2. By Neoantigens Type
- 8.2.3. By Route of Administration
- 8.2.4. By Immunotherapy Type
- 8.2.5. By Country
- 8.3. Europe: Country Analysis
- 8.3.1. France Neoantigen Targeted Therapies Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Target Disease Indication
- 8.3.1.2.2. By Neoantigens Type
- 8.3.1.2.3. By Route of Administration
- 8.3.1.2.4. By Immunotherapy Type
- 8.3.2. Germany Neoantigen Targeted Therapies Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Target Disease Indication
- 8.3.2.2.2. By Neoantigens Type
- 8.3.2.2.3. By Route of Administration
- 8.3.2.2.4. By Immunotherapy Type
- 8.3.3. Spain Neoantigen Targeted Therapies Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Target Disease Indication
- 8.3.3.2.2. By Neoantigens Type
- 8.3.3.2.3. By Route of Administration
- 8.3.3.2.4. By Immunotherapy Type
- 8.3.4. Italy Neoantigen Targeted Therapies Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Target Disease Indication
- 8.3.4.2.2. By Neoantigens Type
- 8.3.4.2.3. By Route of Administration
- 8.3.4.2.4. By Immunotherapy Type
- 8.3.5. United Kingdom Neoantigen Targeted Therapies Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Target Disease Indication
- 8.3.5.2.2. By Neoantigens Type
- 8.3.5.2.3. By Route of Administration
- 8.3.5.2.4. By Immunotherapy Type
9. North America Neoantigen Targeted Therapies Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Target Disease Indication
- 9.2.2. By Neoantigens Type
- 9.2.3. By Route of Administration
- 9.2.4. By Immunotherapy Type
- 9.2.5. By Country
- 9.3. North America: Country Analysis
- 9.3.1. United States Neoantigen Targeted Therapies Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Target Disease Indication
- 9.3.1.2.2. By Neoantigens Type
- 9.3.1.2.3. By Route of Administration
- 9.3.1.2.4. By Immunotherapy Type
- 9.3.2. Mexico Neoantigen Targeted Therapies Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Target Disease Indication
- 9.3.2.2.2. By Neoantigens Type
- 9.3.2.2.3. By Route of Administration
- 9.3.2.2.4. By Immunotherapy Type
- 9.3.3. Canada Neoantigen Targeted Therapies Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Target Disease Indication
- 9.3.3.2.2. By Neoantigens Type
- 9.3.3.2.3. By Route of Administration
- 9.3.3.2.4. By Immunotherapy Type
10. South America Neoantigen Targeted Therapies Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Target Disease Indication
- 10.2.2. By Neoantigens Type
- 10.2.3. By Route of Administration
- 10.2.4. By Immunotherapy Type
- 10.2.5. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Neoantigen Targeted Therapies Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Target Disease Indication
- 10.3.1.2.2. By Neoantigens Type
- 10.3.1.2.3. By Route of Administration
- 10.3.1.2.4. By Immunotherapy Type
- 10.3.2. Argentina Neoantigen Targeted Therapies Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Target Disease Indication
- 10.3.2.2.2. By Neoantigens Type
- 10.3.2.2.3. By Route of Administration
- 10.3.2.2.4. By Immunotherapy Type
- 10.3.3. Colombia Neoantigen Targeted Therapies Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Target Disease Indication
- 10.3.3.2.2. By Neoantigens Type
- 10.3.3.2.3. By Route of Administration
- 10.3.3.2.4. By Immunotherapy Type
11. Middle East and Africa Neoantigen Targeted Therapies Market Outlook
- 11.1. Market Size & Forecast
- 11.2. Market Share & Forecast
- 11.2.1. By Target Disease Indication
- 11.2.2. By Neoantigens Type
- 11.2.3. By Route of Administration
- 11.2.4. By Immunotherapy Type
- 11.2.5. By Country
- 11.3. MEA: Country Analysis
- 11.3.1. South Africa Neoantigen Targeted Therapies Market Outlook
- 11.3.1.1. Market Size & Forecast
- 11.3.1.2. Market Share & Forecast
- 11.3.1.2.1. By Target Disease Indication
- 11.3.1.2.2. By Neoantigens Type
- 11.3.1.2.3. By Route of Administration
- 11.3.1.2.4. By Immunotherapy Type
- 11.3.2. Saudi Arabia Neoantigen Targeted Therapies Market Outlook
- 11.3.2.1. Market Size & Forecast
- 11.3.2.2. Market Share & Forecast
- 11.3.2.2.1. By Target Disease Indication
- 11.3.2.2.2. By Neoantigens Type
- 11.3.2.2.3. By Route of Administration
- 11.3.2.2.4. By Immunotherapy Type
- 11.3.3. UAE Neoantigen Targeted Therapies Market Outlook
- 11.3.3.1. Market Size & Forecast
- 11.3.3.2. Market Share & Forecast
- 11.3.3.2.1. By Target Disease Indication
- 11.3.3.2.2. By Neoantigens Type
- 11.3.3.2.3. By Route of Administration
- 11.3.3.2.4. By Immunotherapy Type
12. Market Dynamics
- 12.1. Drivers
- 12.2. Challenges
13. Market Trends & Developments
- 13.1. Recent Developments
- 13.2. Product Launches
- 13.3. Mergers & Acquisitions
14. Global Neoantigen Targeted Therapies Market: SWOT Analysis
15. Porter's Five Forces Analysis
- 15.1. Competition in the Industry
- 15.2. Potential of New Entrants
- 15.3. Power of Suppliers
- 15.4. Power of Customers
- 15.5. Threat of Substitute Product
16. PESTLE Analysis
17. Competitive Landscape
- 17.1. BioNtech SE
- 17.1.1. Business Overview
- 17.1.2. Company Snapshot
- 17.1.3. Products & Services
- 17.1.4. Financials (In case of listed companies)
- 17.1.5. Recent Developments
- 17.2. Gritstone Bio, Inc.
- 17.3. Genocea Biosciences Inc
- 17.4. Moderna Inc.
- 17.5. Agenus Inc.
- 17.6. Immatics N.V.
- 17.7. Advaxis Inc.
- 17.8. Precision Biologics
- 17.9. Gilead Sciences, Inc.
- 17.10. Cellular Biomedicine Group, Inc.
- 17.11. Achillies Therapeutics Plc.
- 17.12. Merck & Co, Inc.
18. Strategic Recommendations
19. About Us & Disclaimer
